Fosamax and Osteonecrosis of the Jaw: Understanding Long-Term Prognosis

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Analysis

For decades, the public health landscape has been shaped by broad-based initiatives in general health and science information, which have provided foundational knowledge on a wide array of medical topics. Within this legacy, the emphasis has often been on preventive care, treatment efficacy, and the safe use of pharmaceuticals across diverse populations. This generalist approach has served as a critical starting point for understanding how medications interact with the body over time, particularly in the context of long-term therapy for chronic conditions. As the archive of such information has matured, it has become increasingly clear that the scope of inquiry must extend beyond initial prescribing guidelines to encompass the full spectrum of patient outcomes. This evolution naturally leads to a more focused examination of specific adverse events that may arise from prolonged drug exposure, especially when those events carry significant implications for quality of life. One such area of concern involves the use of bisphosphonates, a class of drugs widely prescribed for bone health, and their potential association with rare but serious complications. The transition from a general health framework to a targeted analysis of occupational exposure risk is therefore a logical progression, allowing for a deeper understanding of how therapeutic interventions can, in certain contexts, lead to unexpected and severe consequences.

Fosamax and Osteonecrosis of the Jaw: An Overview

Fosamax (alendronate) is a bisphosphonate medication indicated for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a known adverse effect associated with bisphosphonate use, including Fosamax. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). If severe symptoms develop, discontinuation of the drug is recommended. Most patients had relief of symptoms after stopping, but a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Long-Term Prognosis and Risk Context

Regarding the long-term prognosis of ONJ after Fosamax exposure, evidence from a cohort study among cancer-free female patients aged 40-89 with or at risk for osteoporosis in the United Kingdom Clinical Practice Research Datalink provides quantitative risk estimates. Among female patients treated for osteoporosis, ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). However, absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation of treatment (https://pubmed.ncbi.nlm.nih.gov/39400702/). This suggests that while the relative risk increases with longer exposure, the absolute risk of developing ONJ remains small, and the condition is considered a rare adverse effect of antiresorptive drug use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Mechanistic pathways linking Fosamax to ONJ are not fully detailed in the provided evidence, but a multiscale characterization of jawbone has been noted to provide comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This suggests ongoing research into the biological mechanisms underlying this adverse effect. In terms of risk communication, the prescribing information for Fosamax includes warnings about ONJ, noting its association with bisphosphonate use and identifying known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The adequacy of these warnings is supported by the inclusion of specific risk factors and recommendations for management, such as considering discontinuation before invasive dental procedures. However, the evidence does not provide a direct assessment of whether these warnings are sufficient in practice. For affected patients, prognosis-related considerations include the potential for symptom relief after drug discontinuation, though a subset may experience recurrence upon rechallenge (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The timeline between exposure and documented harm can vary, with symptoms appearing as early as one day or as late as several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ increases with longer duration of bisphosphonate use, but absolute risks remain low and diminish after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the long-term prognosis for osteonecrosis of the jaw after Fosamax exposure?

The long-term prognosis for ONJ after Fosamax exposure is generally favorable for most patients. Symptoms often resolve after discontinuation of the drug, though a subset may experience recurrence if rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Absolute risks of developing ONJ remain low, approximately 0.05% after 5 years, and diminish after stopping treatment (https://pubmed.ncbi.nlm.nih.gov/39400702/).

How does the duration of Fosamax use affect the risk of osteonecrosis of the jaw?

The risk of ONJ increases with longer duration of bisphosphonate use. A cohort study found that among female patients treated for osteoporosis, ONJ risk was threefold higher after 2-3 years and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). However, absolute risks remain low even with prolonged use.

What are the known risk factors for developing osteonecrosis of the jaw while taking Fosamax?

Known risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.